BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//OncoPlanning//Event//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:e369e253-a0f0-4bed-ad83-8bafc7dc1ae5@oncoplanning
DTSTAMP:20260426T212205Z
DTSTART;VALUE=DATE:20251215
DTEND;VALUE=DATE:20251215
SUMMARY:Detection of Minimal Residual Disease (MRD): A Highly Sensitive Tool for Monitoring Cancer Patients
DESCRIPTION:We hope to see many of you at this event!  Don't miss the next Ecosystem Breakfast on the topic: Detection of Minimal Residual Disease (MRD): A Highly Sensitive Tool for Monitoring Cancer Patients  With:   Charles Marcaillou\, Head of R&D\, IntegraGen Charles is a senior scientist and molecular biologist with over 25 years of expertise in genomics and a pioneer in next-generation sequencing technologies. As head of R&D\, he has overseen the development\, validation\, and optimization of the full range of NGS-based applications offered by the company. Séverine Matin-Lannerée\, PhD\, Head of Quality\, IntegraGen Séverine oversees regulatory compliance and quality management for high-throughput sequencing services\, with a focus on applications in clinical research and trials\, including liquid biopsy. She joined IntegraGen in 2017 after a career in academic and translational research on the molecular bases and mechanisms of cancer. She initially led R&D projects within the oncology biomarker team and acted as a scientific advisor. Céline Capéra\, Head of Sales\, IntegraGen Céline has led IntegraGen's Commercial team since 2021. Having joined the team in 2010\, she has helped IntegraGen become a European leader in genomics services and precision medicine. She has a strong background in NGS and genomics technologies
LOCATION:PSCC\, Villejuif\, France
URL:https://www.parissaclaycancercluster.org/event-details/detection-of-minimal-residual-disease-mrd-a-highly-sensitive-tool-for-monitoring-cancer-patients
END:VEVENT
END:VCALENDAR